Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Author-Supplied Keywords:
      KRAS
      mutation
      Pancreatic adenocarcinoma
      SMAD4
      TP53
    • Abstract:
      BACKGROUND: Pancreatic adenocarcinoma (PDAC) is one of the deadliest human malignancies. Although surgery is currently the only effective treatment for PDAC, most patients survive less than 20 months after tumor resection. OBJECTIVE: The primary goal was to investigate alterations in KRAS, TP53, SMAD4 and CDKN2A/p16 in tumors from patients with exceptionally long survival after surgery. METHODS: Tumors from 15 patients with PDAC that survived more than 55 months after surgery ("LS") were analyzed for KRAS, TP53, IDH1, NRAS and BRAF using next-generation sequencing. SMAD4 and CDKN2A/p16 was tested using immunohistochemistry. MGMT promoter methylation was investigated. RESULTS: Tumors from "LS" have a lower prevalence of KRAS and TP53 mutations and had more frequently SMAD4 retained expression, if compared with that of patients died within 24 months from surgery. The survival of patients with wild-type KRAS and TP53 tumors was more than twice longer than that of patients bearing KRAS and TP53 mutations (90.2 vs. 41.1 months). Patients with KRAS wild-type tumors and that retained SMAD4 expression had a survival twice longer than cases with alterations in both genes (83.8 vs. 36.7 months). Eleven tumors (39.3%) showed MGMT methylation. CONCLUSIONS: Our data indicate that absence of KRAS, TP53 and SMAD4 genetic alterations may identify a subset of pancreatic carcinomas with better outcome. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Cancer Biomarkers is the property of IOS Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • Author Affiliations:
      1Surgery Unit, Azienda USL-Maggiore Hospital, Bologna, Italy
      2Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale) – Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna School of Medicine, Bologna, Italy
      3Anatomic Pathology Unit, Azienda USL-Maggiore Hospital, Bologna, Italy
      4Anatomic Pathology Unit, Arcispedale Santa Maria Nuova – IRCCS, Reggio Emilia, Italy
      5Anatomic Pathology Unit, “F. Addarii” Institute of Oncology and Transplantation Pathology, S. Orsola-Malpighi University Hospital, Bologna, Italy
      6Department of Pharmacy and Biotechnology (Dipartimento di Farmacia e Biotecnologie) – Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
      7Internal Medicine Unit, Maggiore Hospital, Bologna, Italy
      8Department of General Surgery and Transplantation, St. Orsola-Malpighi University Hospital, Bologna, Italy
      9Unit of Gastroenterology and Digestive Endoscopy, AUSL Bologna Bellaria-Maggiore Hospital, Bologna, Italy
      10Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale), Cardiology Unit, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy
    • Full Text Word Count:
      7884
    • ISSN:
      1574-0153
    • Accession Number:
      10.3233/CBM-170464
    • Accession Number:
      127980694
  • Citations
    • ABNT:
      MASETTI, M. et al. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Cancer Biomarkers, [s. l.], v. 21, n. 2, p. 323–334, 2018. DOI 10.3233/CBM-170464. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=127980694&custid=s8280428. Acesso em: 9 jul. 2020.
    • AMA:
      Masetti M, Acquaviva G, Visani M, et al. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Cancer Biomarkers. 2018;21(2):323-334. doi:10.3233/CBM-170464.
    • AMA11:
      Masetti M, Acquaviva G, Visani M, et al. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Cancer Biomarkers. 2018;21(2):323-334. doi:10.3233/CBM-170464
    • APA:
      Masetti, M., Acquaviva, G., Visani, M., Tallini, G., Fornelli, A., Ragazzi, M., Vasuri, F., Grifoni, D., Di Giacomo, S., Fiorino, S., Lombardi, R., Tuminati, D., Ravaioli, M., Fabbri, C., Bacchi-Reggiani, M. L., Pession, A., Jovine, E., & de Biase, D. (2018). Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Cancer Biomarkers, 21(2), 323–334. https://doi.org/10.3233/CBM-170464
    • Chicago/Turabian: Author-Date:
      Masetti, Michele, Giorgia Acquaviva, Michela Visani, Giovanni Tallini, Adele Fornelli, Moira Ragazzi, Francesco Vasuri, et al. 2018. “Long-Term Survivors of Pancreatic Adenocarcinoma Show Low Rates of Genetic Alterations in KRAS, TP53 and SMAD4.” Cancer Biomarkers 21 (2): 323–34. doi:10.3233/CBM-170464.
    • Harvard:
      Masetti, M. et al. (2018) ‘Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4’, Cancer Biomarkers, 21(2), pp. 323–334. doi: 10.3233/CBM-170464.
    • Harvard: Australian:
      Masetti, M, Acquaviva, G, Visani, M, Tallini, G, Fornelli, A, Ragazzi, M, Vasuri, F, Grifoni, D, Di Giacomo, S, Fiorino, S, Lombardi, R, Tuminati, D, Ravaioli, M, Fabbri, C, Bacchi-Reggiani, ML, Pession, A, Jovine, E & de Biase, D 2018, ‘Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4’, Cancer Biomarkers, vol. 21, no. 2, pp. 323–334, viewed 9 July 2020, .
    • MLA:
      Masetti, Michele, et al. “Long-Term Survivors of Pancreatic Adenocarcinoma Show Low Rates of Genetic Alterations in KRAS, TP53 and SMAD4.” Cancer Biomarkers, vol. 21, no. 2, Jan. 2018, pp. 323–334. EBSCOhost, doi:10.3233/CBM-170464.
    • Chicago/Turabian: Humanities:
      Masetti, Michele, Giorgia Acquaviva, Michela Visani, Giovanni Tallini, Adele Fornelli, Moira Ragazzi, Francesco Vasuri, et al. “Long-Term Survivors of Pancreatic Adenocarcinoma Show Low Rates of Genetic Alterations in KRAS, TP53 and SMAD4.” Cancer Biomarkers 21, no. 2 (January 2018): 323–34. doi:10.3233/CBM-170464.
    • Vancouver/ICMJE:
      Masetti M, Acquaviva G, Visani M, Tallini G, Fornelli A, Ragazzi M, et al. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Cancer Biomarkers [Internet]. 2018 Jan [cited 2020 Jul 9];21(2):323–34. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=127980694&custid=s8280428